Peptides DB
Research-centric peptide and protocol reference hub
Study 20 of 22PT-141 (Bremelanotide) literatureBioactive materials · Review2026

Real-time sensing-integrated organoid-on-a-chip platforms: Technological progress and emerging biomedical applications.

Sensing-integrated organoid-on-a-chip platforms may revolutionize real-time monitoring in biomedical research, but empirical validation is necessary to confirm their clinical utility.

Read at Bioactive materialsAdd to compare

Where it sits

this study against the rest of the pt-141 (bremelanotide) corpus
7
Preclinical
6
Observational
0
Open-label
2
Randomised
7
Reviews · this one

Summary and findings

This review discusses the development and application of sensing-integrated organoid-on-a-chip platforms. It highlights the integration of real-time sensing technologies to monitor organoid development and function. The potential applications in developmental biology, disease modeling, and drug screening are emphasized.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
2026

Abstract

The authors’ words, as Bioactive materials supplied them

As micro-scale 3D tissues self-organized from stem cells, organoids can highly recapitulate the cellular composition and complex spatial architecture of human organs, establishing themselves as pivotal physiological models in biomedical research. Although organoids offer significant advantages in mimicking human physiological structures, traditional monitoring methodologies predominantly rely on destructive endpoint assays, which fail to capture the transient fluctuations inherent in biological processes. To overcome this limitation, we propose the sensing-integrated organoid-on-a-chip, a frontier interdisciplinary platform. This review systematically outlines the comprehensive construction of this platform, focusing on the synergistic integration of microenvironmental engineering and real-time sensing technologies. The article provides an in-depth analysis of real-time monitoring facilitated by high-performance electrical, optical, and mechanical sensors to quantify organoid developmental maturation, metabolic fluctuations, and pathological evolution. We emphasize the application potential of this platform across developmental biology, disease modeling, drug screening, and neuroscience exploration. Furthermore, we discuss the integration of closed-loop feedback regulation systems and artificial intelligence-assisted analysis, while outlining the trajectory of this platform toward clinical precision medicine and industrial standardization. We firmly believe that sensing-integrated organoid-on-a-chip platforms will accelerate the advancement of personalized diagnosis and therapeutics, thereby ushering in a new era of dynamic biomedical research and intelligent healthcare.

Background

Organoids are micro-scale 3D tissues derived from stem cells that mimic human organ structures, offering significant advantages in biomedical research. Traditional monitoring methods often rely on destructive endpoint assays, which do not capture dynamic biological processes. This study addresses the need for real-time monitoring technologies to enhance the utility of organoids in research and clinical applications.

Methods

This is a review article that systematically outlines the construction and application of sensing-integrated organoid-on-a-chip platforms. It focuses on the integration of microenvironmental engineering with real-time sensing technologies. The review discusses various sensor types, including electrical, optical, and mechanical, and their roles in monitoring organoid development.

Results

The review highlights the capabilities of sensing-integrated platforms to provide real-time data on organoid maturation, metabolic changes, and pathological developments. It emphasizes the potential for these platforms to transform applications in developmental biology, disease modeling, and drug screening.

Interpretation

The integration of real-time sensing technologies with organoid platforms represents a significant advancement in biomedical research. While the review outlines potential applications, the lack of original data means conclusions are speculative. The proposed platforms could enhance precision medicine and industrial standardization, but further empirical validation is needed.

Key findings

  • Real-time monitoring of organoid maturation and metabolic fluctuations.
  • Integration of electrical, optical, and mechanical sensors.
  • Potential applications in disease modeling and drug screening.
  • Discussion of closed-loop feedback regulation systems.
  • Emphasis on artificial intelligence-assisted analysis.

Limitations

  • No original experimental data
  • Focus on potential applications rather than validated outcomes
  • Speculative conclusions without empirical validation

Elsewhere in the PT-141 (Bremelanotide) corpus

DMultifunctional material platforms for neural interfaces: active orchestration of dynamic foreign body response across implantation lifetimes.Bioactive materials · 2026reviewBAn interpretable machine learning model for predicting febrile seizures following enterovirus infection in children.Annals of medicine · 2026 · n=446 · XGBoost model training set AUC was 0.972 (95% CI: 0.958-0.987).HumanDSmart-responsive electrospun scaffolds (SRES) for neural repair: Recent advances and future prospects.Bioactive materials · 2026reviewAHMB supplementation combined with high-intensity functional exercise supports aerobic capacity but not strength in trained and untrained males: a randomized controlled trial.Journal of the International Society of Sports Nutrition · 2026 · n=90 · VO2MAX increased with HMB in TR, p=0.024.HumanDEmerging bioactive microneedle platforms for disease management: From cutaneous disorders to systemic therapeutics.Bioactive materials · 2026reviewBAnalysis of vaccine adverse events associated with rheumatoid arthritis: A pharmacovigilance study based on the VAERS database.Human vaccines & immunotherapeutics · 2026 · n=11532185 · 34,498 RA-related adverse events (0.03%) among 11,532,185 reports.Human